Dr. Francois Bachand, MD
Claim this profileBritish Columbia Cancer Agency Center for the Southern Interior
Studies Prostate Cancer
5 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Francois Bachand, MD is currently running
Radiotherapy
for Prostate Cancer
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.
Recruiting1 award N/A10 criteria
HDR Brachytherapy
for Prostate Cancer
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.
Recruiting1 award N/A
More about Francois Bachand, MD
Clinical Trial Related7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Francois Bachand, MD has experience with
- HDR
- LDR
- HDR Partial Prostate Brachytherapy
- High Dose Rate Prostate Brachytherapy
- Low Dose Rate Prostate Brachytherapy
- High Dose Rate Brachytherapy
Breakdown of trials Francois Bachand, MD has run
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Francois Bachand, MD specialize in?
Francois Bachand, MD focuses on Prostate Cancer and other conditions. In particular, much of their work with Prostate Cancer has involved treating patients, or patients who are undergoing treatment.
Is Francois Bachand, MD currently recruiting for clinical trials?
Yes, Francois Bachand, MD is currently recruiting for 2 clinical trials in Kelowna British Columbia. If you're interested in participating, you should apply.
Are there any treatments that Francois Bachand, MD has studied deeply?
Yes, Francois Bachand, MD has studied treatments such as HDR, LDR, HDR partial prostate brachytherapy.
What is the best way to schedule an appointment with Francois Bachand, MD?
Apply for one of the trials that Francois Bachand, MD is conducting.
What is the office address of Francois Bachand, MD?
The office of Francois Bachand, MD is located at: British Columbia Cancer Agency Center for the Southern Interior, Kelowna, British Columbia V1Y5L3 Canada. This is the address for their practice at the British Columbia Cancer Agency Center for the Southern Interior.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.